Global Actinic Keratosis Drugs Market 2017 to 2021 – Analysis of Almirall, GALDERMA, LEO Pharma, and Valeant

MarketResearchNest.com adds “Global Actinic Keratosis Drugs Market 2017-2021” new reports to its research database. The report spread across 80 pages with tables and figures in it.

The analysts forecast the global actinic keratosis drugs market to grow at a CAGR of 3.32% during the period 2017-2021. Actinic keratosis is a pre-stage non-melanoma skin cancer caused by exposure to ultraviolet (UV) rays. Initially, the skin has a sandpaper-like texture with lesions. It can develop into squamous cell carcinoma, if not treated. The actinic keratosis drugs market includes nucleoside metabolic inhibitors, photosensitizers, nonsteroidal anti-inflammatory drugs (NSAIDs), and immunomodulators.

Get more details about report at https://www.marketresearchnest.com/global-actinic-keratosis-drugs-market-2017-2021.html .

Researcher recognizes the following companies as the key players in the global actinic keratosis drugs market: Almirall, GALDERMA, LEO Pharma, and Valeant.

Other Prominent Vendors in the market are: Biofrontera, Novartis, Perrigo, Promius Pharma, Taro Pharmaceutical Industries, TOLMAR Pharmaceuticals, and Vidac Pharma.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is novel drug delivery mechanisms. The advent of novel drug delivery systems such as microneedles will improve the efficacy and bioavailability of the already marketed formulations. Microneedling has evolved as an adjuvant therapy to the drug treatment available for actinic keratosis.”

Order a Purchase Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=280832 .

According to the report, one driver in the market is high prevalence of actinic keratosis. Actinic keratosis develops mainly due to UV exposure. The lesions arising from actinic keratosis can lead to squamous cell carcinoma if left untreated. With the growing awareness of oncology, people believe in choosing causative treatment. This leads to a higher incidence rate of actinic keratosis treatment, which has been driving the market growth. The prevalence is high in individuals with fair skin and in regions with high exposure to the sun such as those near the equator. As per the NIH, the prevalence rate of actinic keratosis was estimated to be 40%-50% in the Caucasian population aged above 40 years.

Further, the report states that one challenge in the market is alternative treatment options. The availability of better alternative treatment modalities is the biggest challenge for the global actinic keratosis drugs market. The treatment of actinic keratosis through techniques such as cryotherapy and chemical peeling is more popular than treatment through drugs due to their better efficacy. Cryotherapy freezes the cells affected by actinic keratosis by applying liquid nitrogen to the area and thereby stops the disease growth. Considering that such quick therapies save on time and are convenient for patients, their popularity is only expected to grow over time.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Inquire before buying at https://www.marketresearchnest.com/enquirybuy.php?reportid=280832 .

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

This release was published on openPR.